MCRB
Seres Therapeutics, Inc.
There isn't enough reported data to score MCRB yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
MCRB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
MCRB's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
MCRB PE Valuation
MCRB has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
MCRB Forward outlook
There aren't enough analyst estimates for MCRB to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
MCRB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.02 | -910% |
| Q2 2026 | -$2.45 | -122% |
| Q1 2026 | -$5.19 | -157% |
| Q4 2025 | $0.64 | +$0.64 |
| Q3 2025 | $0.62 | +$5.02 |
| Q2 2025 | $11.28 | +$34.68 |
| Q1 2025 | $9.15 | +$20.95 |
| Q4 2024 | $0.00 | +$17.71 |
MCRB has swung to a loss: it lost $5.02 per share over the past year, after a profit the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over MCRB on earnings quality, reporting a profit while its opponent remains loss making.
MCRB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $593K | +69% |
| Q4 2023 | $64K | -93% |
| Q3 2023 | $310K | -91% |
| Q2 2023 | $126.5M | +10301% |
| Q4 2022 | $975K | -86% |
| Q3 2022 | $3.4M | -97% |
| Q2 2022 | $1.2M | -77% |
| Q1 2022 | $1.5M | -74% |
MCRB's revenue is recovering but still below its 2021 peak: $593,000 last quarter, up 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2724% | +3680 points |
| Q2 2026 | -2890% | N/A |
| Q1 2026 | -5840% | N/A |
| Q4 2025 | -4424% | N/A |
| Q3 2025 | -6404% | N/A |
| Q4 2023 | -61759% | -54754 points |
| Q3 2023 | -15295% | -13578 points |
| Q2 2023 | 39% | +5247 points |
MCRB's operating margin was −2724% last quarter, up 3680 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over MCRB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over MCRB on profitability, with a higher operating margin.
MCRB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.5M | -577% |
| Q2 2026 | -$22.4M | -$8.9M |
| Q1 2026 | -$16.4M | -161% |
| Q4 2025 | -$14.7M | +$24.2M |
| Q3 2025 | $2.2M | +$37M |
| Q2 2025 | -$13.5M | +$26.4M |
| Q1 2025 | $26.9M | +$62.2M |
| Q4 2024 | -$39M | +$9.4M |
MCRB has burned cash in almost every quarter: −$64M over the past year, against −$23M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over MCRB on cash generation, producing positive trailing cash flow while its opponent burns cash.
MCRB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.4% | +235K shares |
| 1 year | +14% | +1.2M shares |
| 3 years | +56% | +3.6M shares |
| 5 years | +110% | +5.2M shares |
| Available history | +182% | +6.4M shares |
MCRB has 10M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over MCRB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
MCRB Net Leverage
MCRB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
MCRB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 3.9 | Oversold |
MCRB's weekly RSI is 25 (oversold) and its Stochastic is 4 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
MCRB PE vs Healthcare Sector
| Metric | MCRB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MCRB has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MCRB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.36 | 40% below |
| 20 week MA | $4.08 | 65% below |
| 50 week MA | $7.91 | 82% below |
| 100 week MA | $11.2 | 87% below |
| 200 week MA | $29.8 | 95% below |
MCRB is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over MCRB on trend strength, trading above more of its moving averages.
MCRB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $80.0 | $485.6 | +507% |
| 2021 | $485.6 | $183.4 | -62% |
| 2022 | $183.4 | $104.8 | -43% |
| 2023 | $104.8 | $28.0 | -73% |
| 2024 | $28.0 | $17.7 | -37% |
| 2025 | $17.7 | $14.7 | -17% |
| 2026 YTD | $14.7 | $1.41 | -90% |
MCRB has finished five years in a row lower, and it's down 90% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over MCRB on returns for 2026, with the stronger performance.